Lisa La on Multiple Myeloma Research Coming Out of ASH

Video

The clinical researcher spoke about the research that she is most excited to review at ASH this year.

In an interview with CancerNetwork®, Lisa La, director of clinical research in the Center for Cancer Care at White Plains Hospital, discussed research in multiple myeloma coming out of the 2020 ASH Annual Meeting & Exposition that she looks forward to reviewing.

Transcription:

I have been working in myeloma, just in general research in multiple myeloma, for about 10 years. I recently left Mount Sinai last year of December. So, as I was leaving Mount Sinai, I left a lot of research to good hands. We did a lot of first in human phase 1 trials. I'm very excited to see the data for those first in human phase 1 trials.

For example, the bispecific antibodies targeting GPRC5D and CD3 from Janssen. I’m interested in the Regeneron phase 1, also an antibody. So, I'm interested to see how those patients fared because those are really heavily pretreated relapsed/refractory multiple myeloma patients. So, I'm interested to see, especially patients that were post CAR T, what are their other options, and, you know, CAR T was like the big thing last year and now it's just kind of looking at the safety data and looking at off-the-shelf CAR T for myeloma patients, so I'm excited to see those.

Luckily with this whole virtual ASH, you know, conference, you don't have to be there that day, you know, you can kind of go back and kind of re-review some of the presentations. So, I'm looking to have that opportunity to sit down and just really dive into those.

Related Videos
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Ursula Linne-McLaren, RN, an expert on multiple myeloma